Jounce Therapeutics, Inc. (JNCE:NASDAQ) rocketted at $0.99, a gain of 33.8%. On Wed, Dec 28, 2022, JNCE:NASDAQ touched a New 2-Week High of $0.99. The stock appeared on our News Catalysts scanner on Wed, Dec 28, 2022 at 11:31 AM in the 'BIOTECH' category. From Wed, Dec 14, 2022, the stock recorded 55.56% Up Days and 50.00% Green Days
The stock spiked on Wed, Dec 28, 2022 at $1.27 with a volume of 37M+.
About Jounce Therapeutics, Inc. (JNCE:NASDAQ)
Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in transforming the treatment pf cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients.
Top 10 Gainers:
- Kala Pharmaceuticals, Inc. (KALA:NASDAQ), 218.37%
- Minerva Surgical Inc. (UTRS:NASDAQ), 66.15%
- TransCode Therapeutics Inc. (RNAZ:NASDAQ), 51.82%
- Rubius Therapeutics, Inc. (RUBY:NASDAQ), 45.06%
- Hoth Therapeutics, Inc. (HOTH:NASDAQ), 44.74%
- Gorilla Technology Group Inc. (GRRR:NASDAQ), 42.98%
- Nuwellis Inc. (NUWE:NASDAQ), 37.48%
- Argo Blockchain plc (ARBK:NASDAQ), 36.29%
- Unico American Corporation (UNAM:NASDAQ), 35.96%
- Jounce Therapeutics, Inc. (JNCE:NASDAQ), 33.79%